Vaxart Inc Stock Performance
| VXRT Stock | USD 0.80 0.05 6.67% |
Vaxart holds a performance score of 14 on a scale of zero to a hundred. The entity has a beta of 1.13, which indicates a somewhat significant risk relative to the market. Vaxart returns are very sensitive to returns on the market. As the market goes up or down, Vaxart is expected to follow. Use Vaxart Inc maximum drawdown, skewness, as well as the relationship between the Skewness and day typical price , to analyze future returns on Vaxart Inc.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Vaxart Inc are ranked lower than 14 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively unfluctuating basic indicators, Vaxart unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more
Last Split Factor 1:11 | Dividend Date 2018-02-14 | Ex Dividend Date 2012-11-09 | Last Split Date 2018-02-14 |
1 | Disposition of 54153 shares by Steven Lo of Vaxart at 0.37 subject to Rule 16b-3 | 12/04/2025 |
2 | Vaxart Stock Price Passes Below 200 Day Moving Average - Heres Why - MarketBeat | 12/17/2025 |
3 | Vaxart to Relocate Headquarters Amid Lease Termination - The Globe and Mail | 12/30/2025 |
4 | Vaxart to Participate in the Global BioInnovation Forum on January 13, 2026 | 01/08/2026 |
5 | Vaxart Publishes Positive Data for its Oral Bivalent Norovirus Candidate in Lactating Women and Their Infants | 01/15/2026 |
6 | Acquisition by Wheadon David E. of 95400 shares of Vaxart at 0.7 subject to Rule 16b-3 | 01/23/2026 |
7 | Does Vaxarts Early Norovirus Infant Data Hint At A Broader Oral Vaccine Platform Advantage | 01/27/2026 |
8 | Disposition of 9265 shares by Sean Tucker of Vaxart at 0.6085 subject to Rule 16b-3 | 02/02/2026 |
9 | Acquisition by Sean Tucker of 90000 shares of Vaxart subject to Rule 16b-3 | 02/03/2026 |
10 | Vaxart to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026 | 02/18/2026 |
| Begin Period Cash Flow | 34.8 M | |
| Total Cashflows From Investing Activities | -21.3 M |
Vaxart Relative Risk vs. Return Landscape
If you would invest 38.00 in Vaxart Inc on December 1, 2025 and sell it today you would earn a total of 42.00 from holding Vaxart Inc or generate 110.53% return on investment over 90 days. Vaxart Inc is currently generating 1.5574% in daily expected returns and assumes 8.5025% risk (volatility on return distribution) over the 90 days horizon. In different words, 76% of stocks are less volatile than Vaxart, and 69% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Vaxart Target Price Odds to finish over Current Price
The tendency of Vaxart Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 0.80 | 90 days | 0.80 | about 1.92 |
Based on a normal probability distribution, the odds of Vaxart to move above the current price in 90 days from now is about 1.92 (This Vaxart Inc probability density function shows the probability of Vaxart Stock to fall within a particular range of prices over 90 days) .
Vaxart Price Density |
| Price |
Predictive Modules for Vaxart
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Vaxart Inc. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Vaxart Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Vaxart is not an exception. The market had few large corrections towards the Vaxart's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Vaxart Inc, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Vaxart within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 1.45 | |
β | Beta against Dow Jones | 1.13 | |
σ | Overall volatility | 0.14 | |
Ir | Information ratio | 0.18 |
Vaxart Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Vaxart for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Vaxart Inc can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Vaxart Inc is way too risky over 90 days horizon | |
| Vaxart Inc has some characteristics of a very speculative penny stock | |
| Vaxart Inc appears to be risky and price may revert if volatility continues | |
| Vaxart Inc has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 28.7 M. Net Loss for the year was (66.95 M) with loss before overhead, payroll, taxes, and interest of (30.88 M). | |
| Vaxart Inc currently holds about 129.55 M in cash with (44.76 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.02, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Vaxart Inc has a poor financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: Fortress Biotech The PRV Catalyst That Could Reprice This Microcap - Seeking Alpha |
Vaxart Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Vaxart Stock often depends not only on the future outlook of the current and potential Vaxart's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Vaxart's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 487.3 M | |
| Cash And Short Term Investments | 51.7 M |
Vaxart Fundamentals Growth
Vaxart Stock prices reflect investors' perceptions of the future prospects and financial health of Vaxart, and Vaxart fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Vaxart Stock performance.
| Return On Equity | -1.07 | ||||
| Return On Asset | -0.16 | ||||
| Profit Margin | (0.34) % | ||||
| Operating Margin | (0.11) % | ||||
| Current Valuation | 177.5 M | ||||
| Shares Outstanding | 240.06 M | ||||
| Price To Book | 7.13 X | ||||
| Price To Sales | 1.30 X | ||||
| Revenue | 28.7 M | ||||
| Gross Profit | (30.88 M) | ||||
| EBITDA | (54.87 M) | ||||
| Net Income | (66.95 M) | ||||
| Cash And Equivalents | 129.55 M | ||||
| Cash Per Share | 1.02 X | ||||
| Total Debt | 23.28 M | ||||
| Debt To Equity | 0.09 % | ||||
| Current Ratio | 8.65 X | ||||
| Book Value Per Share | 0.12 X | ||||
| Cash Flow From Operations | (44.76 M) | ||||
| Earnings Per Share | (0.22) X | ||||
| Market Capitalization | 192.05 M | ||||
| Total Asset | 166.39 M | ||||
| Retained Earnings | (476.52 M) | ||||
| Working Capital | (22.62 M) | ||||
About Vaxart Performance
Assessing Vaxart's fundamental ratios provides investors with valuable insights into Vaxart's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Vaxart is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 100.19 | 53.42 | |
| Return On Tangible Assets | (0.49) | (0.51) | |
| Return On Capital Employed | (1.01) | (0.96) | |
| Return On Assets | (0.46) | (0.44) | |
| Return On Equity | (1.31) | (1.24) |
Things to note about Vaxart Inc performance evaluation
Checking the ongoing alerts about Vaxart for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Vaxart Inc help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Vaxart Inc is way too risky over 90 days horizon | |
| Vaxart Inc has some characteristics of a very speculative penny stock | |
| Vaxart Inc appears to be risky and price may revert if volatility continues | |
| Vaxart Inc has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 28.7 M. Net Loss for the year was (66.95 M) with loss before overhead, payroll, taxes, and interest of (30.88 M). | |
| Vaxart Inc currently holds about 129.55 M in cash with (44.76 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.02, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Vaxart Inc has a poor financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: Fortress Biotech The PRV Catalyst That Could Reprice This Microcap - Seeking Alpha |
- Analyzing Vaxart's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Vaxart's stock is overvalued or undervalued compared to its peers.
- Examining Vaxart's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Vaxart's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Vaxart's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Vaxart's stock. These opinions can provide insight into Vaxart's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Vaxart Stock Analysis
When running Vaxart's price analysis, check to measure Vaxart's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxart is operating at the current time. Most of Vaxart's value examination focuses on studying past and present price action to predict the probability of Vaxart's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxart's price. Additionally, you may evaluate how the addition of Vaxart to your portfolios can decrease your overall portfolio volatility.